Generic drugmakers aren't wasting time anticipating Pfizer's loss of patent coverage on Lipitor. A handful of copycat drugmakers have filed with the FDA for approval of their versions of the blockbuster cholesterol drug. Report
Generic drugmakers aren't wasting time anticipating Pfizer's loss of patent coverage on Lipitor. A handful of copycat drugmakers have filed with the FDA for approval of their versions of the blockbuster cholesterol drug. Report